PKM and neoplasm: The tumor suppressor NDRG2 inhibits metabolic reprogramming through a dual mechanism: it directly reduces PKM2 expression, limiting pyruvate production, while concurrently inhibiting c-Myc transcriptional activity, which in turn suppresses GLUT1- and HK2-mediated glucose uptake and phosphorylation (72).